Technology Appraisal Guidance No. 186
Source: National Institute for Health and Care Excellence
1.1 Certolizumab pegol is recommended as an option for the treatment of people with rheumatoid arthritis only if:
- certolizumab pegol is used as described for other tumour necrosis factor (TNF) inhibitor treatments in ‘Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis' (NICE technology appraisal guidance 130) and
- the manufacturer provides the first 12 weeks of certolizumab pegol (10 pre-loaded 200-mg syringes) free of charge to all patients starting treatment.
1.2 When using the DAS28 (as set out in NICE technology appraisal guidance 130), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to the DAS28 and make any adjustments they consider appropriate.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA186
An abridged version of this guidance (a 'quick reference guide') is also available. Printed copies of the quick reference guide can be obtained by contacting 0845 003 7783 or emailing email@example.com and quoting reference number N2106. It is also available on the Internet at http://guidance.nice.org.uk/TA186/QuickRefGuide/pdf/English
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Certolizumab pegol for the treatment of rheumatoid arthritis
Issue Date: February 2010
Review Date: September 2010